Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 8/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 6/20 | 0.34 |
| ▸ | HTR1A | P08908 | 6/20 | 0.34 |
| ▸ | HTR2A | P28223 | 6/20 | 0.34 |
| ▸ | HTR6 | P50406 | 6/20 | 0.34 |
| ▸ | GHSR | Q92847 | 4/20 | 0.34 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.33 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25900302 | 0.83 | CYP2D6 (0.36) | HTR7IP6K1GHSRIP6K3IP6K2 | |
| SCHEMBL25316575 | 0.79 | BACE1 (0.35) | — | |
| SCHEMBL31178347 | 0.79 | BACE1 (0.35) | — | |
| SCHEMBL30506996 | 0.77 | STS (0.39) | IP6K1IP6K3IP6K2TNKSTNKS2 | |
| SCHEMBL25318001 | 0.77 | STS (0.39) | IP6K1IP6K3IP6K2TNKSTNKS2 | |
| SCHEMBL30507144 | 0.74 | KDM4E (0.33) | HTR7HTR1AHTR2AHTR6 | |
| SCHEMBL25318608 | 0.74 | KDM4E (0.33) | HTR7HTR1AHTR2AHTR6 | |
| SCHEMBL21626938 | 0.72 | OPRM1 (0.39) | HTR7HTR1AHTR2AHTR6GHSR | |
| SCHEMBL25926295 | 0.71 | HTR7 (0.44) | HTR7IP6K1HTR1AHTR2AHTR6 | |
| SCHEMBL31584751 | 0.70 | PGR (0.44) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | HTR7 3454/4885IP6K1 3004/4885HTR1A 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.